BiOptix receives additional $1.4M in funding

Optical biodetection company BiOptix has received an additional $1.4 million in financing from existing investors, which will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand.

Aug. 19, 2014

Optical biodetection company BiOptix (Boulder, CO) has received an additional $1.4 million in financing from existing investors, which will be used to expand sales and marketing and ramp up manufacturing to meet growing customer demand.

Related: Advances in optical biodetection

Rick Whitcomb, BiOptix's CEO, explains that the company sees opportunity in the label-free marketplace, which is looking for a high-performance surface plasmon resonance (SPR) instrument at a "reasonable price." SPR measures refractive index changes in a sensor chip's gold surface due to a change in mass that occurs during a binding event.

The company has developed and patented a novel, ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance (ESPR), which pairs the high sensitivity of SPR with the high stability and lower noise of common-path interferometry.

-----

Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!